ADVITOS

company

About

ADVITOS developed the CE-marked and globally patented ADVOS technology.

  • 51 - 100

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
€20M
Founded date
Jan 1, 2005
Number Of Employee
51 - 100
Operating Status
Active

ADVOS is the world’s first method for the combined multi-organ support of liver, lung, kidney, and acid-base balance. Based on the principle of albumin dialysis, ADVOS allows extracorporeal fluid-based elimination of CO2, hepatic toxins, water-soluble and protein-bound nephrotoxins, as well as the correction of metabolic and respiratory acidosis. The ADVOS method works with typical dialysis accesses and flow rates and does not require any gas exchangers for CO2 elimination.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
€20M
ADVITOS has raised a total of €20M in funding over 2 rounds. Their latest funding was raised on Jun 10, 2021 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 10, 2021 Series Unknown €20M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
ADVITOS is funded by 1 investors. European Innovation Council are the most recent investors.
Investor Name Lead Investor Funding Round
European Innovation Council Series Unknown